Oppenheimer Raises Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $51.00

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […]

Related Keywords

,Corbus Pharmaceuticals Holdings Inc ,Corbus Pharmaceuticals ,Institutional Investors Weigh In On Corbus Pharmaceuticals ,Corbus Pharmaceuticals Company Profile ,Corbus Pharmaceuticals Trading ,News Ratings For Corbus Pharmaceuticals Daily ,Vident Investment Advisory ,Securities Exchange Commission ,Renaissance Technologies ,Dimensional Fund Advisors ,Free Report ,Get Free Report ,Cormorant Asset Management ,Exchange Commission ,Sigma Investments ,Fund Advisors ,Investment Advisory ,Street Corp ,Pharmaceuticals Holdings ,Corbus Pharmaceuticals Daily ,Nasdaq Crbp ,Crbp ,Medical ,Boost Price Target ,Oppenheimer Holdings Inc ,